Related Experiment Video
Updated: Jul 10, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies
O Ibraghimov-Beskrovnaya1, N Bukanov
1Cell Biology, Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701-9322, USA. oxana.beskrovnaya@genzyme.com
Abstract:
Polycystic kidney diseases (PKDs) represent a large group of progressive renal disorders characterized by the development of renal cysts leading to end-stage renal disease. Enormous strides have been made in understanding the pathogenesis of PKDs and the development of new therapies. Studies of autosomal dominant and recessive polycystic kidney diseases converge on molecular mechanisms of cystogenesis, including ciliary abnormalities and intracellular calcium dysregulation, ultimately leading to increased proliferation, apoptosis and dedifferentiation. Here we review the pathobiology of PKD, highlighting recent progress in elucidating common molecular pathways of cystogenesis. We discuss available models and challenges for therapeutic discovery as well as summarize the results from preclinical experimental treatments targeting key disease-specific pathways.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Nephrons
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

